PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2016 January; 60(1): 621–623.
Published online 2015 December 31. Prepublished online 2015 October 19. doi:  10.1128/AAC.01211-15
PMCID: PMC4704236

Multidrug-Resistant Neisseria gonorrhoeae Isolates from Nanjing, China, Are Sensitive to Killing by a Novel DNA Gyrase Inhibitor, ETX0914 (AZD0914)

Abstract

We tested the activity of ETX0914 against 187 Neisseria gonorrhoeae isolates from men with urethritis in Nanjing, China, in 2013. The MIC50, MIC90, and MIC range for ETX0914 were 0.03 μg/ml, 0.06 μg/ml, and ≤0.002 to 0.125 μg/ml, respectively. All isolates were resistant to ciprofloxacin, and 36.9% (69/187) were resistant to azithromycin. Of the isolates, 46.5% were penicillinase-producing N. gonorrhoeae (PPNG), 36% were tetracycline-resistant N. gonorrhoeae (TRNG), and 13% (24 isolates) had an MIC of 0.125 μg/ml for ceftriaxone. ETX0914 may be an effective treatment option for gonorrhea.

TEXT

In the absence of an effective gonococcal vaccine, the prevention and control of gonorrhea depend on early diagnosis and effective antimicrobial therapy for patients at risk for acquiring infection and their sex partners. Currently, the first-line agents for the treatment of gonorrhea in most countries are extended-spectrum cephalosporins (ESCs), such as cefixime and ceftriaxone. However, gonococcal strains with reduced susceptibility or frank resistance to ESCs have emerged, and treatment failures with the oral agent cefixime (1,5) and injectable ceftriaxone have been documented in several countries (6,10).

ETX0914 (also known as AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor, which functions by inhibiting DNA biosynthesis and stabilizing cleaved covalent complexes of gyrase and double-stranded broken DNA. This results in the blockage of religation of the double-strand cleaved DNA to form fused circular DNA (11). ETX0914 has displayed potent in vitro antibacterial activity against N. gonorrhoeae, including multidrug-resistant strains, certain Gram-positive organisms, such as Staphylococcus aureus and Streptococcus pneumoniae, and fastidious Gram-negative organisms, such as Haemophilus spp. and Moraxella catarrhalis, and also atypical and anaerobic organisms (12,15). Cross-resistance between ETX0914 and fluoroquinolones has not been observed (16). The rates of resistance in N. gonorrhoeae to ciprofloxacin and other antimicrobials have been high in China (17,21). Our previous study showed that 99.8% of the N. gonorrhoeae strains isolated from symptomatic men attending a sexually transmitted diseases (STD) clinic in Nanjing, China, between April 2011 and December 2012 were resistant to ciprofloxacin (22). Here, we investigated the in vitro activity of ETX0914 against 187 clinical gonococcal strains isolated from men with gonococcal urethritis attending this clinic a year later in 2013, and we compared the activity of ETX0914 to that of other currently or previously used antimicrobials administered for the treatment of gonorrhea.

The Gram stains of 177/187 urethral exudates showed polymorphonuclear leukocytes (PMNs) and Gram-negative intracellular diplococci, criteria that are highly specific (>99%) for gonococcal infection (2324). Urethral swab specimens from men with urethritis were also inoculated onto Thayer-Martin medium (DL Biotech, China) and cultured in candle jars at 36°C. Gonococcal isolates were identified by colonial morphology, Gram stain, and oxidase testing. The MICs (in micrograms per milliliter) of N. gonorrhoeae to ETX0914, penicillin, tetracycline, ciprofloxacin, spectinomycin, azithromycin, cefixime, and ceftriaxone were determined by agar gel dilution. N. gonorrhoeae ATCC 49226, WHO references A, G, and J, and a ceftriaxone-resistant strain (25) were used as quality controls. MIC breakpoints for assigning susceptible, intermediate, and resistance statuses to N. gonorrhoeae isolates for penicillin, tetracycline, ciprofloxacin, spectinomycin, cefixime, and ceftriaxone were determined according to CLSI standards (26). Interpretative criteria from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (www.eucast.org) (27) were used for azithromycin. The production of β-lactamase was identified by filter paper acidometric testing that used bromocresol purple as a pH indicator (28). IBM SPSS Statistics version 22.0 was used for statistical analysis. The Mann-Whitney test was used for pairwise comparisons between groups.

All isolates of N. gonorrhoeae were inhibited by concentrations of ≤0.125 μg/ml of ETX0914; the MIC50, MIC90, and MIC range of ETX0914 were 0.03 μg/ml, 0.06 μg/ml, and ≤0.002 to 0.125 μg/ml (Table 1), respectively. The results of susceptibility testing of other antibiotics are shown in Table 2. All isolates were resistant to ciprofloxacin (MIC, ≥1 μg/ml); the MIC50 and MIC90 were both ≥8 μg/ml. The MICs of gonococcal strains for ETX0914 were lower than those for ciprofloxacin (P < 0.0001), with a median 256-fold difference. The MIC distributions of ETX0914 and ciprofloxacin for all isolates are shown in Fig. 1.

TABLE 1
Distribution of ETX0914 MICs for 187 clinical N. gonorrhoeae isolates
TABLE 2
Susceptibility categories and MICs of seven antimicrobials previously or currently used for treatment of gonorrhea against 187 clinical N. gonorrhoeae isolates
FIG 1
MIC distributions of ETX0914 and ciprofloxacin for 187 clinical N. gonorrhoeae isolates.

Of the isolates, 36.9% (69/187) were resistant to azithromycin (MIC, ≥1 μg/ml), and nine displayed high-level azithromycin resistance (MIC, ≥256 μg/ml). Also, 74.3% (139/187) and 87.2% (163/187) of isolates were resistant to penicillin and tetracycline, respectively. Of the isolates, 46.5% (87/187) were penicillinase-producing N. gonorrhoeae (PPNG), and 36.4% (68/187) were tetracycline-resistant N. gonorrhoeae (TRNG). The MIC50 and MIC90 for ETX0914 were 0.03 μg/ml and 0.06 μg/ml, respectively, for β-lactamase-producing isolates, which are the same as or lower than those for β-lactamase-negative strains. Of the isolates, 28.9% (54/187) were resistant to ciprofloxacin, penicillin G, tetracycline, and azithromycin.

All isolates were susceptible to spectinomycin (MIC, ≤32 μg/ml), cefixime (MIC, ≤0.25 μg/ml), and ceftriaxone (MIC, ≤0.125 μg/ml). However, 5 isolates (2.7%) had elevated MICs for cefixime (≥0.125 μg/ml), and 24 isolates (12.8%) had an MIC of 0.125 μg/ml for ceftriaxone (the breakpoint). The MIC90s for ETX0914 and cefixime were the same (0.06 μg/ml), but the MIC90 for ceftriaxone was greater (0.125 μg/ml). The MIC for ETX0914 for the Spanish ceftriaxone-resistant strain was 0.06 μg/ml.

We tested the antimicrobial activity of a new spiropyrimidinetrione molecule, ETX0914 (also known as AZD0914), against clinical gonococcal isolates. A high prevalence of resistance was observed for antimicrobials that had been used in the past but that have been put aside. Moreover, 28.8% of the isolates showed multidrug resistance, i.e., resistance to ciprofloxacin, penicillin, tetracycline, and azithromycin; however, all isolates were inhibited by ≤0.125 μg/ml ETX0914. Isolates of N. gonorrhoeae with borderline high MICs for ceftriaxone (0.125 μg/ml) had corresponding MICs for ETX0914 that were 8- to 21-fold lower (0.016 to 0.06 μg/ml). The in vitro results of this study demonstrated that the antimicrobial activity of ETX0914 was superior to that of ciprofloxacin and several other antimicrobials currently or previously recommended for the treatment of gonorrhea. ETX0914, like ciprofloxacin, is a type II topoisomerase poison, but the interactions with DNA gyrase subunits differ between the two antibiotics (11).

Our results concur with those of other studies (13, 14) that have shown ranges of MICs, MIC50, and MIC90 of ETX0914 for international reference strains of N. gonorrhoeae and clinical isolates from European countries to be 0.002 to 0.25 μg/ml, 0.064 to 0.125 μg/ml, and 0.125 to 0.25 μg/ml, respectively.

In conclusion, ETX0914 has excellent antimicrobial activity against clinical isolates of N. gonorrhoeae, including high-level ciprofloxacin-resistant and otherwise multiresistant strains. ETX0914 may be an effective treatment option for gonorrhea.

ACKNOWLEDGMENTS

We thank J. Camara for providing the ceftriaxone-resistant N. gonorrhoeae isolate.

X.-H.S. directed the project, supervised the bacterial isolate collection, and prepared the manuscript. W.-J.L., Y.-R.L., C.W., and S.L. carried out the antimicrobial susceptibility testing and identification of the tetM- and β-lactamase gene-producing plasmid. B.-X.W. directed the project and consulted on manuscript preparation. P.A.R., R.A.A., and J.P.M. consulted on the project and manuscript preparation. All authors read and approved the final manuscript.

We declare no conflicts of interest.

Funding Statement

This work was supported in part by NIH/NIAID grant no. U19AI084048.

REFERENCES

1. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H 2010. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 15:pii=19721 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19721. [PubMed]
2. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S 2011. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 16:pii=19833 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19933. [PubMed]
3. Unemo M, Golparian D, Stary A, Eigentler A 2011. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill 216:pii=19998 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19998. [PubMed]
4. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P 2012. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 56:1273–1280. doi:.10.1128/AAC.05760-11 [PMC free article] [PubMed] [Cross Ref]
5. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE 2013. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 309:163–170. doi:.10.1001/jama.2012.176575 [PubMed] [Cross Ref]
6. Tapsall J, Read P, Carmody C, Bourne C, Ray S, Limnios A, Sloots T, Whiley D 2009. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol 58:683–687. doi:.10.1099/jmm.0.007641-0 [PubMed] [Cross Ref]
7. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H, Kitawaki J 2011. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 17:148–149. doi:.10.3201/eid1701.100397 [PMC free article] [PubMed] [Cross Ref]
8. Unemo M, Golparian D, Hestner A 2011. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 16:pii=19792 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19792. [PubMed]
9. Unemo M, Golparian D, Potočnik M, Jeverica S 2012. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. Euro Surveill 17:20200 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20200. [PubMed]
10. Golparian D, Ohlsson A, Janson H, Lidbrink P, Richtner T, Ekelund O, Fredlund H, Unemo M 2014. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill 19:20862 http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20862. [PubMed]
11. Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, Doig P, Fan J, Gao N, Mills SD, Mueller J, Sriram S, Thresher J, Walkup GK 2015. Inhibition of Neisseria gonorrhoeae type II topoisomerases by the novel spiropyrimidinetrione AZD0914. J Biol Chem 290:20984–20994. doi:.10.1074/jbc.M115.663534 [PMC free article] [PubMed] [Cross Ref]
12. Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter ME, Miller PF, Mueller JP 2015. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob Agents Chemother 59:467–474. doi:.10.1128/AAC.04124-14 [PMC free article] [PubMed] [Cross Ref]
13. Jacobsson S, Golparian D, Alm RA, Huband M, Mueller J, Jensen JS, Ohnishi M, Unemo M 2014. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585–5588. doi:.10.1128/AAC.03090-14 [PMC free article] [PubMed] [Cross Ref]
14. Unemo M, Ringlander J, Wiggins C, Fredlund H, Jacobsson S, Cole M 2015. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother 59:5220–5225. doi:.10.1128/AAC.00786-15 [PMC free article] [PubMed] [Cross Ref]
15. Biedenbach DJ, Huband MD, Hackel M, de Jonge BL, Sahm DF, Bradford PA 2015. In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens. Antimicrob Agents Chemother 59:6053–6063. doi:.10.1128/AAC.01016-15 [PMC free article] [PubMed] [Cross Ref]
16. Alm RA, Lahiri SD, Kutschke A, Otterson LG, McLaughlin RE, Whiteaker JD, Lewis LA, Su X, Huband MD, Gardner H, Mueller JP 2015. Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59:1478–1486. doi:.10.1128/AAC.04456-14 [PMC free article] [PubMed] [Cross Ref]
17. Su X, Jiang F, Qimuge, Dai X, Sun H, Ye S 2007. Surveillance of antimicrobial susceptibilities in Neisseria gonorrhoeae in Nanjing, China, 1999–2006. Sex Transm Dis 34:995–999. [PubMed]
18. Yang Y WL ZC, Gu W 2009. Study of antimicrobial susceptibilities and molecular resistance determines in Neisseria gonorrhoeae isolated in Shanghai. Chin J Lab Med 32:1173–1175.
19. Gu W, Chen Y, Yang Y, Wu L, Hu W, Jin Y 2014. Twenty-five-year changing pattern of gonococcal antimicrobial susceptibility in Shanghai: surveillance and its impact on treatment guidelines. BMC Infect Dis 14:731. doi:.10.1186/s12879-014-0731-9 [PMC free article] [PubMed] [Cross Ref]
20. Zheng H, Yang B, Wu X, Huang J, Zeng W, Xue Y, Qin X, Lan Y, Tang S, Ou J, Li Y 2014. Antibiotic susceptibility of Neisseria gonorrhoeae isolates from Guangzhou, China, during 2002–2011. Jpn J Infect Dis 67:288–291. doi:.10.7883/yoken.67.288 [PubMed] [Cross Ref]
21. Cao WL, Liang JY, Li XD, Bi C, Yang RD, Liang YH, Li P, Zhong DQ, Ye XD, Zhang XB 2015. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated from Guangzhou, China, 2000 to 2005 and 2008 to 2013. Sex Transm Dis 42:27–29. doi:.10.1097/OLQ.0000000000000218 [PubMed] [Cross Ref]
22. Li S, Su XH, Le WJ, Jiang FX, Wang BX, Rice PA 2014. Antimicrobial susceptibility of Neisseria gonorrhoeae isolates from symptomatic men attending the Nanjing sexually transmitted diseases clinic (2011–2012): genetic characteristics of isolates with reduced sensitivity to ceftriaxone. BMC Infect Dis 14:622. doi:.10.1186/s12879-014-0622-0 [PMC free article] [PubMed] [Cross Ref]
23. Tapsall J. 2001. Antimicrobial resistance in Neisseria gonorrhoeae. WHO/CDS/CSR/DRS/2001.3. World Health Organization, Geneva, Switzerland: http://www.who.int/drugresistance/Antimicrobial_resistance_in_Neisseria_gonorrhoeae.pdf.
24. Workowski KA, Bolan GA 2015. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommend Rep 64(RR03):61. [PubMed]
25. Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C 2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 67:1858–1860. doi:.10.1093/jac/dks162 [PubMed] [Cross Ref]
26. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement CLSI document M100-S22 Clinical and Laboratory Standards Institute, Wayne, PA.
27. European Committee on Antimicrobial Susceptibility Testing. 2012. Breakpoint tables for interpretation of MICs and zone diameters: version 1.3. European Committee on Antimicrobial Susceptibility Testing, Växjö, Sweden: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf.
28. Sng EH, Yeo KL, Rajan VS 1981. Simple method for detecting penicillinase-producing Neisseria gonorrhoeae and Staphylococcus aureus. Br J Vener Dis 57:141–142. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)